Bristol Myers Squibb vs. Pfizer: Better High-Yield Dividend Stock?
An analysis comparing Bristol Myers Squibb (BMY) and Pfizer (PFE) as high-yield dividend stock options. The article emphasizes dividend durability over yield as the key factor for investors.
According to a report from Motley Fool, the comparison between Bristol Myers Squibb (BMY) and Pfizer (PFE) as high-yield dividend stocks requires focusing on dividend durability rather than just yield size.
Dividend Durability
Durability refers to a company's ability to maintain or increase dividends over time, regardless of economic fluctuations. This factor is more important than a high yield that may be unsustainable.
Comparison Between the Two Companies
Bristol Myers Squibb (BMY)
Bristol Myers has a long history of dividend payments, with a strong drug portfolio in oncology and immunology. However, it faces challenges from patent expirations on some key drugs.
Pfizer (PFE)
Pfizer has a broad and diverse portfolio, but its dividends have been impacted by declining COVID-19 vaccine revenues. The current yield may be high but potentially unsustainable.
What This Means for Investors
An investor seeking steady income should prefer the company with more sustainable dividends, even if its yield is lower. Fundamental analysis suggests Bristol Myers may be the safer long-term choice, but the final decision depends on individual investor goals.
Frequently Asked Questions
Found this useful? Share it